Background: Increasingly, liposomal bupivacaine is being used with multimodal pain management strategies. In vitro investigations have shown decreased chondrotoxicity profiles for liposomal bupivacaine; however, there is no evidence regarding its in vivo effects.
Multimodal pain management strategies after orthopaedic surgery have been found to result in decreased postoperative pain scores, as well as decreased narcotic pain medication use.
14 Numerous studies have investigated various medications and strategies, including local anesthetics, nerve stabilization agents, nerve blocks, and premedication. 4, 28, 31, 33 One of the more recent medications to be introduced into these strategies is liposomal bupivacaine.
Chondrocyte death is a recognized sequelae after exposure of articular cartilage to anesthetic agents, as seen in clinical reports of chondrolysis after intra-articular infusion pump administration in shoulder and knee procedures. 22, 24 In vitro studies have demonstrated that the degree of chondrocyte death is related to the specific agent used, with bupivacaine resulting in greater death than ropivacaine. 3, 26, 27 In addition, the pH of the solution, solution preservative, and combined epinephrine usage have been shown to influence the degree of toxicity. 10 These findings have been reproduced with in vivo animal models, showing inhibition of proteoglycan synthesis and chondrocyte cell density in treated animals. 6, 13, 30 Liposomal bupivacaine is a multi vesicular, liposomal formulation of bupivacaine that has been shown to produce prolonged postinfiltration analgesia. 1, 32 Several studies have investigated its use after total joint arthroplasty with mixed results. 9, 17 As a formulation of bupivacaine, it is not approved for intra-articular infiltration given the known chondrotoxicity of bupivacaine. 3, 26, 27, 30 Shaw et al 29 reported on the in vitro chondrotoxicity, finding no difference in chondrocyte viability between control samples and samples treated for 1 hour with liposomal bupivacaine. The delayed bupivacaine release 16 and more alkaline pH 27 of the liposomal formulation may account for an apparent decreased chondrotoxicity in comparison with plain bupivacaine, but without a longer term analysis in an in vivo setting, no further conclusions can be drawn from these results. No studies to date have investigated the in vivo chondrotoxicity of liposomal bupivacaine.
We sought to perform an in vivo assessment of the chondrotoxicity of liposomal bupivacaine after intra-articular infiltration in a porcine model. We hypothesized that liposomal bupivacaine-treated joints would demonstrate decreased chondrotoxicity in comparison with joints treated with standard bupivacaine.
METHODS
The local institutional animal care and use committee (IACUC) approved the experimental investigation. A porcine model was chosen due to the similarities in joint size, weightbearing requirements, and cartilage thickness compared with the human condition. 8 Juvenile, female Yorkshire cross piglets (Sus scrofa), aged 4 to 6 months and weighing 25 to 30 kg, were used. Using the data reported by Shaw et al, 29 an a priori analysis demonstrated an expected power of .0.8 with 3 samples per group and an alpha of .05. As such, a total of 8 animals were included in this study with 4 animals in each of the treatment groups.
Sedation was induced using an intramuscular injection with 1.0 mg/kg xylazine (Lloyd Inc), 5.5 mg/kg Tiletamine HCl and Zolazepam HCl (Telazol; Zoetis Inc), 0.05 mg/kg atropine sulfate (RX Veterinary Products), and 0.03 mg/kg buprenorphine HCl (Zoetis Inc). Once adequate analgesia was obtained as determined by response to a toe pinch, the animal was positioned in a lateral position (Figure 1) , and the extremity was cleaned with a 4% chlorhexidine scrub (Becton, Dickinson and Company) followed by 70% isopropyl alcohol (Owens & Minor).
The stifle joint was localized by palpation, and the point of injection was demarcated just lateral to the patellar tendon (Figure 2 ), corresponding with a lateral infrapatellar arthroscopy portal. Under ultrasonographic guidance (M-TURBO; SonoSite Inc) (Figure 3 ), a sterile injection of 5 mL of either 1.3% liposomal bupivacaine (66.5 mg of bupivacaine, Exparel; Pacira Pharmaceutical, Inc) or 0.5% bupivacaine (25 mg bupivacaine; Hospira) was performed using a 20-gauge spinal needle placed into the intercondylar notch.
Study animals were randomly assigned into 1 of 2 groups of 4 animals based on injection with either liposomal bupivacaine or standard bupivacaine. Each animal received 1 injection, with the contralateral side serving as a control. The laterality of injection was randomly assigned with use of a randomization calculator. After injection, a sterile dressing was applied, and animals were housed in pens and allowed to feed ad libitum.
Seven days after injection, each animal was euthanized with an overdose of pentobarbital, and cartilage samples were harvested. Samples were obtained using a 4-mm punch biopsy extending to the subchondral bone. One sample was procured from the medial femoral condyle (MFC) and the lateral femoral condyle (LFC) of each animal for chondrocyte viability testing ( Figure 4 ).
Chondrocyte Viability
Chondrocyte viability was performed using a live-dead staining protocol. After euthanasia, samples were harvested from the osteochondral explant using a 4-mm punch biopsy extending to the subchondral bone from the predetermined locations. Samples were stained in a 96-well plate sequentially with ethidium homodimer-2 followed by calcein acetoxymethyl ester (calcein AM, LIVE/DEAD Viability/ Cytotoxicity Kit; Invitrogen, Ltd, Molecular Probes, Inc), at a concentration of 1.0 mM for 30 minutes at 37°C as previously described. 32 Three washes with phosphate-buffered saline were carried out for each sample for 1 minute after each staining and before fluorescent illumination. Confocal microscopy was performed using a Zeiss Observer Z1confocal microscope equipped with a krypton-argon laser (Carl Zeiss Iberia). Z-axis projections were assembled from images made from the cartilage surface to a depth of 200 mm, at intervals of 40 mm. Samples were scanned at wavelengths . Automated ratios of red-and green-stained chondrocytes in each of the 6 sections were calculated and summated. The corresponding percentage of viable cells was calculated from the cumulative values of red-to green-stained chondrocytes (green-stained chondrocytes/[red 1 greenstained chondrocytes] 3 100). The ratio of nonviable to viable chondrocytes for each specimen was calculated by comparing the calculated percentages for the 3 different projections according to the X, Y, and Z axes. This process was repeated for each sample tested for each treatment group. Once sampling had been completed, samples underwent appropriate disposal.
Histology
Samples from the medial and lateral condyle were harvested using a 4-mm punch biopsy. After decalcification and sectioning at 5-mm intervals, they were stained with hematoxylin and eosin (Sigma-Aldrich Co LLC) and safranin O (Sigma-Aldrich Co LLC) by standard protocol. Chondrocyte degeneration was assessed using the modified Mankin score for cartilage structure and cellular appearance. 21, 25 Samples were assessed by a veterinary histopathologist who was blinded to the study design and treatment groups.
Statistical Analysis
Statistical analyses were performed using SPSS statistical software version 21 (IBM). Experimental groups were analyzed using mixed-design analysis of variance (ANOVA) with anesthetic condition (control, bupivacaine, liposomal bupivacaine) serving as the between-subject measure and laterality (LFC, MFC) serving as the within-group variable. Statistical significance was predetermined as P \ .05. Post hoc analysis of power was performed to ensure acceptable power for experimental conditions. 
RESULTS
The cumulative data for chondrocyte viability assessed with calcein AM/ethidium homodimer staining are reported in Table 1 . A high degree of variability was observed in our samples for the control and 0.5% bupivacaine groups. Given the small sample size, the authors took a conservative approach toward eliminating outliers. Two outliers were identified as being greater than 2 SDs from their respective means, one from the control and one from the liposomal bupivacaine group, both representing LFC samples. Variation in chondrotoxicity was demonstrated across the treatment groups ( Figure 5) , as well as between medial and lateral condylar samples ( Figure 6 ). The within-subject ANOVA showed significantly higher mean cell ratios for LFC (5.38 6 29.17) than for MFC (5.08 6 3.99), F 1,9 = 84.55, P \ .01. A significant interaction between area studied (LFC, MFC) and treatment group was observed, F 2,9 = 57.57, P \ .01. In addition, a significant main effect occurred based on the treatment group, as shown by F 2,9 = 28.25, P \ .001. Pairwise comparisons revealed significantly more chondrocyte death in the bupivacaine group (33% nonviable cells) in comparison with liposomal bupivacaine (6.2%) and control (5.8%) groups (P \ 0.01). No differences were observed between the control and liposomal bupivacaine conditions for the MFC or LFC samples (P = .95). Post hoc analyses revealed increased chondrocyte death to the LFC in the bupivacaine group relative to the other 2 treatment groups, whereas no statistical difference was found between the 3 conditions on the MFC side.
Post hoc analysis of power was 1.00 for all main effects. The effect size for the sample laterality (LFC vs MFC) was hp 2 = .924, hp 2 = .943 for the interaction between condition and side, and hp 2 = .89 for anesthetic condition. The effect sizes on the LFC side between the bupivacaine group and the control and liposomal bupivacaine groups were noteworthy: d = 6.38 and d = 5.38, respectively. The post hoc analysis of power found was .99.
Histologic samples of the 3 treatment groups are depicted in Figure 7 . Examination according to the modified Mankin criteria demonstrated no differences between the 3 study groups in terms of cartilage structure and cellular appearance.
DISCUSSION
The clinical use of liposomal bupivacaine has expanded, particularly in the field of orthopaedic surgery where postsurgical pain relief is one of the top 2 factors correlated with overall patient satisfaction. 15 Numerous studies have reported on the efficacy of liposomal bupivacaine with regard to postoperative pain control, narcotic usage, hospital length of stay, and hospital costs, largely in the setting of joint arthroplasty. 5, 9, 33 Despite inconsistencies in technical application and clinical results, there is growing evidence to support improved pain control, decreased breakthrough pain medication use, and earlier ambulation. 11, 18, 33 Translation of these clinical benefits to nonarthroplasty cases has been slow, as liposomal bupivacaine is not currently approved for use in nerve blocks or intra-articular application. Bupivacaine is recognized as a known chondrotoxic agent, despite its widespread clinical use. 23 Following reports of chondrolysis after intra-articular infusion pumps, 22, 24 in vitro studies have shown that chondrotoxicity from local anesthetics is modifiable based on agent concentration, solution preservative, presence of epinephrine, and the particular anesthetic agent. 6, 10, 13, 26, 27, 30 These results have been confirmed with in vivo protocols, highlighting the sensitivity of chondrocytes.
We found that the chondrocyte viability on a cellular level, represented by the calcein AM/ethidium homodimer staining, after treatment with 1.3% liposomal bupivacaine was not significantly different when compared with untreated control samples, and bupivacaine showed significantly less chondrocyte viability. However, histologic comparison between the 3 groups showed no difference in cellular surface integrity, chondrocyte appearance, or viability. Previous studies have shown that calcein AM/ ethidium homodimer staining overestimates the viability of chondrocyte when compared with counterstains and cellular yields in allograft articular cartilage. 19 The results of Lightfoot et al 19 suggested that this variation was the result of persistent enzymatic activity that activated calcein AM staining, as shown by increasing viability results for the first 7 days after harvest.
Our data suggested, however, that although there was chondrocyte death, representing ethidium homodimer fluorescence, histologically there was no difference in cartilage appearance. Numerous studies have been performed that have investigated the effect of local anesthetics on chondrocyte viability using calcein AM/ethidium homodimer and other cellular staining protocols 2, 7, 10, 20, 26, 30 ; however, only a select number of studies have included histologic analysis in their analysis of chondrocyte viaibility. 12, 13, 25 Further studies are needed to characterize the differences in viability between cellular staining and histologic appearance.
These data confirm the in vitro cellular staining results reported by Shaw et al, 29 demonstrating increased chondrocyte viability when compared with bupivacaine-and ropivacaine-treated samples. They also support the hypothesis that the toxic effects of bupivacaine are the result of timedependent exposure of bupivacaine to the chondrocyte, as shown by the lack of significant chondrocyte death in the liposomal bupivacaine group when compared with the control samples, despite the dosage of bupivacaine being more than double that used in the standard bupivacaine. After administration of liposomal bupivacaine, there is a prolonged release of bupivacaine extending for 96 hours, with an initial peak within the first hour and a second peak between 12 and 36 hours afterward, as the medications elute from the liposomal vesicle. This delivery system maintains the anesthetic effects of bupivacaine treatment while preventing maximal concentration exposure. Additional support for the concentration-dependent chondrotoxicity is seen with the intrasubject variation in chondrocyte viability for the bupivacaine-treated subjects, with peak elevations in chondrocyte death located at the site of injection (LFC vs MFC).
This study is not without its limitations. As an animal model, the extrapolation of these data is limited. We chose a porcine model for its similarities to human joint size, weightbearing requirements, and cartilage thickness. 8 In addition, the use of juvenile animals ensured the minimization of confounding articular cartilage damage. We did not use a saline-treated control group. Previous studies have demonstrated that saline-treated samples exhibit a significant difference in chondrocyte viability when compared with virgin knees. 30 As such, we wished to identify the maximal chondrotoxic effects of liposomal bupivacaine in comparison with our control group and elected for an untreated sample. The duration of this study was only 7 days. Although this does extend beyond the prolonged bupivacaine release through 96 hours after administration, 16 previous in vivo studies have shown continued chondrocyte death after local anesthetic administration up to 5 months. 30 Given the discrepancy in viability data between the cellular and histologic assessment, additional in vivo studies are needed of longer duration to definitively assess the long-term effect of liposomal bupivacaine on articular cartilage. In conclusion, this study demonstrated that liposomal bupivacaine has comparable chondrocyte viability when compared with an untreated control. Single injection of standard bupivacaine showed significant differences in the cellular staining for chondrocyte viability; however, there was no difference histologically after short-term exposure. A location-dependent mechanism for the difference in chondrocyte viability of bupivacaine is suggested, however. This study highlights the dichotomy between fluorescent staining and histologic appearance of articular chondrocytes in short-term analyses of viability. These data support the peri-articular application of liposomal bupivacaine in the setting of preserved articular cartilage.
